

## Corporate Action and Result Calendar

 Nov 28<sup>th</sup> – Dec 03<sup>rd</sup> 2022

 To join our research group on TELEGRAM, please click on the links - <https://bit.ly/3HbUtQV> and <https://bit.ly/2YFpdbn>
**Bonus**

Company	Ratio	Ex-Date
7NR RETAIL LTD	5:1	28-Nov-22
JANUS CORPORATION LTD	3:4	28-Nov-22
NAVODAY ENTERPRISES LTD	1:1	29-Nov-22

**Split**

Company	Ratio	Ex-Date
CHANDRA PRABHU INTERNATIONAL LTD	1:5	30-Nov-22
LIKHITHA INFRASTRUCTURE LTD	1:2	01-Dec-22
MEFCOM CAPITAL MARKET LTD	1:5	02-Dec-22

**Right**

Company	Ratio	Ex-Date
--	--	--
--	--	--

**Buyback**

Company	Ex Date	Start Date	End Date	Offer Price
CARE RATINGS LTD	--	18-11-2022	01-12-2022	515
--	--	--	--	--
--	--	--	--	--

**Open Offer**

Company	Start Date	End Date	Offer Price
--	--	--	--

**Dividend for Nov 28<sup>th</sup> – Dec 03<sup>rd</sup> 2022**

Company	Type	Dividend (In Rs)	Ex-Date
Family Care Hospitals Ltd	Interim Dividend	0.05	28-Nov-22
Vedanta Limited	Interim Dividend	17.5	29-Nov-22
MILKFOOD LTD.	Interim Dividend	2.5	30-Nov-22
GUJARAT THEMIS BIOSYN LTD.	Interim Dividend	4.4	1-Dec-22
SOM DISTILLERIES & BREWERIESLTD	Interim Dividend	0.25	2-Dec-22

**Board Meetings for Nov 28<sup>th</sup> – Dec 03<sup>rd</sup> 2022**

Company	Meeting Date	Purpose
APTUS	28-Nov-22	Interim Dividend
CANFINHOME	28-Nov-22	Interim Dividend;General
FUSION	28-Nov-22	Quarterly Results;General
GOKULAGRO	28-Nov-22	Right Issue of Equity Shares;General
GRADIENTE	28-Nov-22	Preferential Issue of shares
VALECHAENG	28-Nov-22	Quarterly Results
WANBURY	28-Nov-22	Quarterly Results
ALANKIT	29-Nov-22	Preferential Issue of shares;General
COMSYN	29-Nov-22	General
DDIL	29-Nov-22	General
IMCAP	29-Nov-22	Preferential Issue of shares
JCTLTD	29-Nov-22	Quarterly Results
LANDMARC	29-Nov-22	General
PHARMAID	29-Nov-22	Preferential Issue of shares;General
RANJEET	29-Nov-22	Increase in Authorised Capital;Preferential Issue of shares
RCF	29-Nov-22	Interim Dividend
SBIN	29-Nov-22	General
SYMBIOX	29-Nov-22	General
TIHIL	29-Nov-22	Issue Of Warrants
TRADWIN	29-Nov-22	Quarterly Results
WELCURE	29-Nov-22	Increase in Authorised Capital;Preferential Issue of shares
DHARFIN	30-Nov-22	Quarterly Results
EIGHTY	30-Nov-22	General
GLCL	30-Nov-22	A.G.M.
ICL	30-Nov-22	Stock Split
JANUSCORP	30-Nov-22	Bonus issue
KPIGREEN	30-Nov-22	Bonus issue;General
SIKOZY	30-Nov-22	General
AML	1-Dec-22	General
EASEMYTRIP	1-Dec-22	General
NAVODAYENT	1-Dec-22	Bonus issue
PRUDMOULI	1-Dec-22	General
SABTN	1-Dec-22	General
STL	1-Dec-22	Stock Split
VEERENRGY	1-Dec-22	Bonus issue;General
JOINDRE	2-Dec-22	General

**Result Calendar for Nov 28<sup>th</sup> – Dec 03<sup>rd</sup> 2022**

DATE:			
--	--	--	--
--	--	--	--

Note: Selection Criteria: BSE 500 Companies. The data is subject to change owing to corporate announcements or rescheduling of board meetings by companies post releasing of the report.

Research Analyst Registration No.	Contact	Website	Email Id
INH00002764	SMS: 'Arihant' to 56677	<a href="http://www.arihantcapital.com">www.arihantcapital.com</a>	<a href="mailto:arihant.research@arihantcapital.co">arihant.research@arihantcapital.co</a> <a href="#">m</a>

**Arihant is Forbes Asia's '200 Best under a \$Billion' Company  
'Best Emerging Commodities Broker' awarded by UTV Bloomberg**

**Disclaimer:** This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. Receipt and review of this document constitutes your agreement not to circulate, redistribute, retransmit or disclose to others the contents, opinions, conclusion, or information contained herein. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said persons may have acted upon and/or in a manner contradictory with the information contained here and may have a position or be otherwise interested in the investment referred to in this document before its publication. The user of this report assumes the entire risk of any use made of this data / Report. Arihant especially states that it has no financial liability, whatsoever, to the users of this Report.

### Arihant Capital Markets Ltd

#1011, Solitaire Corporate Park, Building No.10, 1<sup>st</sup> Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai-400093  
T. 022-42254800. Fax: 022-42254880

[www.arihantcapital.com](http://www.arihantcapital.com)